Ultra-Fast radiation zaps skin cancer in new pilot trial
NCT ID NCT07608549
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study will test a new type of radiation called FLASH radiotherapy for people with cutaneous lymphoma, a rare skin cancer. Ten participants will receive a single, ultra-fast dose of radiation to their skin lesions. The main goal is to see if the treatment is safe and to measure how much radiation reaches the tumor.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- electron FLASH radiotherapy (ultra-high dose rate radiation delivered via Mobetron device)
- What this could lead to
- If successful, this could show that FLASH radiotherapy is a safe and effective way to treat skin lymphoma lesions with fewer side effects than standard radiation.
- What could go wrong
- This is a very early pilot study with only 10 participants, so results may not apply to everyone. The main goal is safety, not yet proving the treatment works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 10 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2029
An estimate. Start dates often move.
- Expected to finish
-
Dec 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Histologic proof of cutaneous lymphoma. 2. The cutaneous lymphoma is not planned to be treated with definitive, higher dose radiotherapy therapy. 3. Participant is planned to receive a course of palliative radiation therapy at DHMC for a cutaneous lymphomas lesion located on an extremity (see appendix A) that can be encompassed in a field size no larger than 7.5 cm in diameter. 4. No prior history of radiotherapy to the site of planned treatment. 5. Patient agrees to discontinue topical therapy, including steroid creams or chemotherapy agents, to the index lesion 4 weeks prior to the radiation treatment. 6. Participant must be capable of providing informed consent or has an acceptable surrogate capable of providing consent on behalf of the participant. 7. Adults at least 18 years of age 8. Eastern Cooperative Oncology Group performance status of \<3. 9. Women of childbearing potential (WOCBP): Premenopausal females who had at least one menstrual cycle in the past 12-months and capable to become pregnant, must have a negative serum beta-HCG pregnancy test result within seven days prior to start of treatment. 10. WOCBP who are sexually active must agree at study entry to use adequate methods of contraception during treatment. Exclusion Criteria: 1. Prior radiotherapy to the site of treatment. 2. Index lesion UHDR treatment field is \<5cm from the field edge of a synchronously treated CONV lesion. 3. Patient receiving prescribed hormonal therapies. 4. Patients with known NCI CTCAE V5.0 grade 3 or higher active systemic or cutaneous viral, bacterial, or fungal infection. 5. Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol. 6. Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent process.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cutaneous lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.